VMDMEDIUM SIGNALOPERATIONAL10-K

VMD significantly expanded its service scope beyond respiratory care into chronic care and women's health while delivering strong 20.5% revenue growth and improved profitability.

The strategic pivot from pure-play respiratory services to a broader chronic care and women's health platform represents a meaningful business model evolution that could expand VMD's addressable market. The company also upgraded from NASDAQ Capital Market to the main NASDAQ exchange, indicating improved market standing and compliance with higher listing standards.

Comparing 2026-03-04 vs 2025-03-10View on EDGAR →
FINANCIAL ANALYSIS

VMD delivered strong operational performance with revenue growing 20.5% to $270.3M while operating income expanded 28.2% to $22.9M, demonstrating improving operational leverage. Operating cash flow surged 32.8% to $51.9M despite a 23% decline in cash position to $13.5M, suggesting the company is effectively converting earnings to cash while potentially investing in growth initiatives. The 27.1% increase in total liabilities warrants monitoring, though it appears manageable given the strong revenue and cash flow growth.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+32.8%
$39.1M$51.9M

Operating cash flow surged 32.8% — exceptional cash generation, highest quality earnings signal.

Net Income
P&L
+32.6%
$11.3M$14.9M

Net income grew 32.6% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+28.2%
$17.9M$22.9M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Total Liabilities
Balance Sheet
+27.1%
$43.8M$55.6M

Liabilities increased 27.1% — monitor debt-to-equity ratio and interest coverage.

Cash & Equivalents
Balance Sheet
-23%
$17.5M$13.5M

Cash decreased 23% — monitor burn rate and upcoming capital needs.

Revenue
P&L
+20.5%
$224.3M$270.3M

Revenue growing 20.5% — solid top-line momentum, watch margins for quality of growth.

Inventory
Balance Sheet
+16.8%
$4.3M$5.0M

Inventory built 16.8% — monitor whether demand supports this build or if write-downs may follow.

Gross Profit
P&L
+16.7%
$133.2M$155.5M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

SG&A Expense
P&L
+14.3%
$106.2M$121.4M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Total Assets
Balance Sheet
+12.5%
$177.1M$199.2M

Asset base grew 12.5% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2026-03-04
PRIOR — 2025-03-10
ADDED
As of February 20, 2026, there were 38,602,631 common shares of the registrant outstanding.
(the "Company" or "Viemed"), through its subsidiaries, is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women s health products and services.
Viemed s primary objective is to drive growth by increasing the number of patients served and the level of care provided through its technology-enabled, home-based clinical care and chronic disease management model.
As of December 31, 2025, the Company employed 401 licensed RTs, representing approximately 29% of the Company-wide employee count.
Viemed expects to continue to be a solution to the rising health costs in the United States by offering more cost-effective, home-based solutions while increasing the quality of life for patients managing chronic and complex health conditions.
+7 more — sign up free →
REMOVED
As of February 18, 2025, there were 39,521,618 common shares of the registrant outstanding.
(the "Company" or "Viemed"), through its subsidiaries, is a provider of home medical equipment ("HME") and post-acute respiratory healthcare services in the United States.
Viemed s primary objective is to focus on the organic growth of the business and thereby solidify its position as one of the United States' largest providers of in-home therapy for patients suffering from respiratory diseases.
As of December 31, 2024, we employed 404 licensed RTs, representing approximately 34% of our company-wide employee count.
Viemed expects to continue to be a solution to the rising health costs in the United States by offering more cost-effective, home-based solutions while increasing the quality of life for patients fighting serious respiratory diseases.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
HOFTHIGHHOFT completed a major divestiture of its Pulaski and Samuel Lawrence furniture ...
2026-04-17
CTRNHIGHCTRN underwent a dramatic operational turnaround with a complete repositioning f...
2026-04-15
ORBSHIGHORBS has undergone a complete business transformation from packaging and e-comme...
2026-04-15
BRFHHIGHBRFH completed a transformative acquisition of Arps Dairy in October 2025, drama...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →